Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. (25th July 2018)

• Record Type: Journal Article
• Authors: Fujigaki, Seiji; Nishiumi, Shin; Kobayashi, Takashi; Suzuki, Makoto; Iemoto, Takao; Kojima, Takashi; Ito, Yoshinori; Daiko, Hiroyuki; Kato, Ken; Shouji, Hirokazu; Honda, Kazufumi; Azuma, Takeshi; Yoshida, Masaru
• Is Part Of: Biomarkers in medicine. Volume 12:Number 8(2018)
• Page Start: 827
• Page End: 840
• Publication Date: 2018-07-25
• Subjects: 5-fluorouracil -- chemoradiosensitivity -- cisplatin -- esophageal squamous cell carcinoma -- metabolomics -- neoadjuvant therapy -- predictive biomarkers -- targeted metabolomics analysis; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2017-0449
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC).Materials & methods: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, was performed.Results: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the six metabolites (arabitol, betaine, glycine, L-serine, L-arginine and L-aspartate). The serum levels of the four metabolites (arabitol, glycine, L-serine and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p = 0.0086, 0.0345, 0.0106 and 0.0373, respectively).Conclusion: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.